These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10875030)

  • 1. Effects of intravenous dofetilide in patients with frequent premature ventricular contractions: a clinical trial.
    Pool PE; Singh SN; Friedrich T
    Clin Cardiol; 2000 Jun; 23(6):415-6. PubMed ID: 10875030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.
    Frost L; Mortensen PE; Tingleff J; Platou ES; Christiansen EH; Christiansen N
    Int J Cardiol; 1997 Jan; 58(2):135-40. PubMed ID: 9049678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.
    Krahn AD; Klein GJ; Yee R
    Pacing Clin Electrophysiol; 2001 Aug; 24(8 Pt 1):1258-60. PubMed ID: 11523612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris.
    Sedgwick ML; Rasmussen HS; Cobbe SM
    Am J Cardiol; 1992 Dec; 70(18):1432-7. PubMed ID: 1442614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
    Boriani G; Lubinski A; Capucci A; Niederle R; Kornacewicz-Jack Z; Wnuk-Wojnar AM; Borggrefe M; Brachmann J; Biffi M; Butrous GS;
    Eur Heart J; 2001 Dec; 22(23):2180-91. PubMed ID: 11913480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy and Safety of Wenxin Keli in Patients with Frequent Premature Ventricular Contractions: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial.
    Hua W; Gao RL; Zhao BC; Wang J; Chen XH; Cai C; Zhang S
    Chin Med J (Engl); 2015 Oct; 128(19):2557-64. PubMed ID: 26415790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
    N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation.
    Mazur A; Anderson ME; Bonney S; Roden DM
    J Am Coll Cardiol; 2001 Mar; 37(4):1100-5. PubMed ID: 11263615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial.
    Køber L; Bloch Thomsen PE; Møller M; Torp-Pedersen C; Carlsen J; Sandøe E; Egstrup K; Agner E; Videbaek J; Marchant B; Camm AJ;
    Lancet; 2000 Dec; 356(9247):2052-8. PubMed ID: 11145491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide.
    Brendorp B; Elming H; Jun L; Køber L; Malik M; Jensen GB; Torp-Pedersen C;
    Circulation; 2001 Mar; 103(10):1422-7. PubMed ID: 11245647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide.
    Brendorp B; Elming H; Jun L; Køber L; Torp-Pedersen C;
    Clin Cardiol; 2003 May; 26(5):219-25. PubMed ID: 12769249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias.
    Echt DS; Lee JT; Murray KT; Vorperian V; Borganelli SM; Crawford DM; Friedrich T; Roden DM
    J Cardiovasc Electrophysiol; 1995 Sep; 6(9):687-99. PubMed ID: 8556189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group.
    Bashir Y; Thomsen PE; Kingma JH; Møller M; Wong C; Cobbe SM; Jordaens L; Campbell RW; Rasmussen HS; Camm AJ
    Am J Cardiol; 1995 Nov; 76(14):1040-4. PubMed ID: 7484858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans.
    Geelen A; Brouwer IA; Schouten EG; Maan AC; Katan MB; Zock PL
    Am J Clin Nutr; 2005 Feb; 81(2):416-20. PubMed ID: 15699229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide.
    Mosller M
    Clin Cardiol; 1997 Aug; 20(8):704-10. PubMed ID: 9259163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure.
    Brendorp B; Elming H; Jun L; Køber L; Torp-Pedersen C;
    Eur J Heart Fail; 2002 Mar; 4(2):201-6. PubMed ID: 11959050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.
    Tendera M; Wnuk-Wojnar AM; Kulakowski P; Malolepszy J; Kozlowski JW; Krzeminska-Pakula M; Szechinski J; Droszcz W; Kawecka-Jaszcz K; Swiatecka G; Ruzyllo W; Graff O
    Am Heart J; 2001 Jul; 142(1):93-8. PubMed ID: 11431663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study.
    Pedersen OD; Brendorp B; Elming H; Pehrson S; Køber L; Torp-Pedersen C
    Card Electrophysiol Rev; 2003 Sep; 7(3):220-4. PubMed ID: 14739717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cibenzoline for symptomatic ventricular arrhythmias: a prospective, randomized, double-blind, placebo controlled trial and a long term open label study.
    Lee MA; Fenster PE; Garcia ZM; Kipps JE; Huang SK
    Can J Cardiol; 1989 Sep; 5(6):295-8. PubMed ID: 2477130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH; Pollak A; Singh SN; Friedrich T
    J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.